ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

ObsEva Appoints Will Brown as Chief Financial Officer

Symposium on oral GnRH antagonists and personalized therapeutic approaches for women with uterine fibroids to be hosted Friday, December 10 at 1 p.m. CET

ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

Cocrystal Pharma

CTI BioPharma

Eton Pharmaceuticals Inc

These biotech penny stocks could be worth watching after recent announcements The post 4 Biotech Penny Stocks to Watch With New Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks to Watch With New Catalysts

GENEVA, Switzerland December 2 , 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced a symposium and three oral presentations on linzagolix, an oral GnRH antagonist, at the 7th Society of Endometriosis and Uterine Disorders (SEUD) Congress being held virtually and in Stockholm, Sweden as a hybrid event from December 9-11, 2021.

ObsEva Announces Symposium and Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021

American Resources Corp

Foresight Autonomous Hlds

Gerdau

Esports Entertainment Group

Marrone Bio Innovations

Vertex Energy

These penny stocks remain positioned to run upwards in the near term. Purchasing shares in December could quickly lead to profits.

7 Hot Penny Stocks to Buy for December That Are Positioned to Pop

The FDA has accepted for review ObsEva SA's (NASDAQ: OBSV) marketing application for linzagolix to manage heavy menstrual bleeding associated with uterine fibroids in premenopausal women. The submission is based on data from the two Phase 3 PRIMROSE trials.

ObsEva Shares Jump After Linzagolix Application For Uterine Fibroids Goes Under FDA Review

The stock price of Obseva SA (NASDAQ: OBSV) increased by over 15% pre-market today. This is why it happened.

Obseva (OBSV) Stock: Why The Price Jumped Today

FDA Accepts NDA for Linzagolix for the Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids

Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix

Obseva Announces Appointment of Stephanie Brown to its Board of Directors

IMARA

Comstock Mining

Synchronoss

Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.

7 Penny Stocks to Book Profits on Before 2022

- Linzagolix f or uterine fibroids: Pending regulatory approval in the US and Europe with commercial planning efforts underway -

ObsEva Announces Third Quarter 2021 Financial Results and Business Update

ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American Society for Reproductive Medicine (ASRM) 2021 Scientific Congress & Expo.

ObsEva Presents Linzagolix Data From Uterine Fibroid Trials

- Final results from pilot study of linzagolix for the treatment of severe adenomyosis to be presented in a second poster -

ObsEva Presents Clinical Data on Oral GnRH Antagonist Linzagolix for the Treatment of Uterine Fibroids at ASRM 2021 Scientific Congress & Expo

– Presentation of Phase 3 clinical data on linzagolix for the treatment of uterine fibroids and final results from a pilot study of linzagoli x for the treatment of severe adenomyosis –

ObsEva Announces Presentation of Clinical Data on Oral GnRH Antagonist Linzagolix at ASRM 2021 Scientific Congress & Expo

ObsEva Announce s Relationship with Syneos Health to Commercialize Linzagolix

ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix

Bitfarms Ltd

Borr Drilling Ltd

Baytex Energy

Hive Blockchain Technologies Ltd

SNDL Inc.

Electrameccanica

These penny stocks have huge potential and solid business fundamentals. As not-so speculative names, they could surge higher sooner or later.

7 Hot Penny Stocks to Buy in Q4 for 10-Bagger Potential

ObsEva Announces Appointment of Luigi Marro as Chief Transformation Officer

ObsEva (OBSV) submits an NDA to the FDA for linzagolix as a potential treatment for uterine fibroids.

ObsEva (OBSV) Files NDA for Linzagolix to Treat Uterine Fibroids

- If approved, linzagolix will be the only GnRH antagonist with flexible dose regimen options to address the clinical needs of more women with uterine fibroids -

ObsEva Announces Submission of New Drug Application to U.S. FDA for Linzagolix for the Treatment of Uterine Fibroids

GENEVA, Switzerland September 7 , 202 1 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Company Management will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15, 2021.

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Bellus Health Inc

Pieris Pharma

These penny stocks could be in focus as we turn the page on a new month. The post 5 Penny Stocks To Watch For September With Upcoming Events appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Penny Stocks To Watch For September With Upcoming Events

Genius Brands

Ring Energy

Timber Pharmaceuticals

Penny stocks from companies that have reasonable business fundamentals. Stocks that can possibly provide multi-fold returns.

7 Hottest Penny Stocks to Pick Up Now

OBSV develops products for female reproductive health and pregnancy.

ObsEva: Developing Treatments For Women

- Linzagolix (Yselty ® ) for uterine fibroids: US New Drug Application filing planned in Q 3 :21 ; European marketing approval recommendation anticipated in Q4:21 -

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

- A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patient s Across Three Randomized , Placebo-Controlled Clinical Trials Published in the Journal of Human Reproduction-

News for ObsEva Stock (OBSV)